Targets for immunotherapy of liver cancer

Journal of Hepatology

Volumn 68, Issue 1, 2018, Pages 157-166

  Greten, Tim F ^a   Sangro, Bruno ^b  

^a NATIONAL CANCER INSTITUTE   (United States)

^b UNIVERSITY CLINIC OF NAVARRA   (Spain)

Author keywords

Cancer; HCC; Immunotherapy

Indexed keywords

ANTINEOPLASTIC AGENT; APATINIB; AVADOMIDE; CAPMATINIB; CHECKPOINT KINASE INHIBITOR; DURVALUMAB; FGF 401; GALUNISERTIB; IPILIMUMAB; LENVATINIB; NINTEDANIB; NIVOLUMAB; PDR 001; PEMBROLIZUMAB; PEXASTIMOGENE DEVACIREPVEC; RAMUCIRUMAB; SHR 1210; SORAFENIB; TICILIMUMAB; UNCLASSIFIED DRUG; XL 888;

CANCER IMMUNOTHERAPY; CELL THERAPY; CHEMOEMBOLIZATION; HUMAN; LIVER CELL CARCINOMA; PRIORITY JOURNAL; REVIEW;

EID: 85034582677     PISSN: 01688278     EISSN: 16000641     Source Type: Journal    
DOI: 10.1016/j.jhep.2017.09.007     Document Type: Review

References (52)

1. Llovet, J.M., Zucman-Rossi, J., Pikarsky, E., Sangro, B., Schwartz, M., Sherman, M., et al. Hepatocellular carcinoma. Nat Rev Dis Primers, 2, 2016, 16018.
2. Bruix, J., Qin, S., Merle, P., Granito, A., Huang, Y.-H., Bodoky, G., et al. Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 389 (2017), 56–66.
3. Greten, T.F., Manns, M.P., Korangy, F., Immunotherapy of hepatocellular carcinoma. J Hepatol 45 (2006), 868–878.
4. Greten, T.F., Manns, M.P., Korangy, F., Immunotherapy of HCC. Rev Recent Clin Trials 3 (2008), 31–39.
5. Couzin-Frankel, J., Breakthrough of the year 2013. Cancer immunotherapy. Science 342 (2013), 1432–1433.
6. Prieto, J., Melero, I., Sangro, B., Immunological landscape and immunotherapy of hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 12 (2015), 681–700.
7. Le Mercier, I., Lines, J.L., Noelle, R.J., Beyond CTLA-4 and PD-1, the generation Z of negative checkpoint regulators. Front Immunol, 6, 2015, 418.
8. Wing, K., Onishi, Y., Prieto-Martin, P., Yamaguchi, T., Miyara, M., Fehervari, Z., et al. CTLA-4 control over Foxp3+ regulatory T cell function. Science 322 (2008), 271–275.
9. Han, Y., Chen, Z., Yang, Y., Jiang, Z., Gu, Y., Liu, Y., et al. Human CD14+ CTLA-4+ regulatory dendritic cells suppress T-cell response by cytotoxic T-lymphocyte antigen-4-dependent IL-10 and indoleamine-2,3-dioxygenase production in hepatocellular carcinoma. Hepatology 59 (2014), 567–579.
10. Barber, D.L., Wherry, E.J., Masopust, D., Zhu, B., Allison, J.P., Sharpe, A.H., et al. Restoring function in exhausted CD8 T cells during chronic viral infection. Nature 439 (2006), 682–687.
11. Anderson, A.C., Tim-3: an emerging target in the cancer immunotherapy landscape. Cancer Immunol Res 2 (2014), 393–398.
12. Nguyen, L.T., Ohashi, P.S., Clinical blockade of PD1 and LAG3–potential mechanisms of action. Nat Rev Immunol 15 (2015), 45–56.
13. Triebel, F., Jitsukawa, S., Baixeras, E., Roman-Roman, S., Genevee, C., Viegas-Pequignot, E., et al. LAG-3, a novel lymphocyte activation gene closely related to CD4. J Exp Med 171 (1990), 1393–1405.
14. Sedy, J.R., Gavrieli, M., Potter, K.G., Hurchla, M.A., Lindsley, R.C., Hildner, K., et al. B and T lymphocyte attenuator regulates T cell activation through interaction with herpesvirus entry mediator. Nat Immunol 6 (2005), 90–98.
15. Watanabe, N., Gavrieli, M., Sedy, J.R., Yang, J., Fallarino, F., Loftin, S.K., et al. BTLA is a lymphocyte inhibitory receptor with similarities to CTLA-4 and PD-1. Nat Immunol 4 (2003), 670–679.
16. Sangro, B., Gomez-Martin, C., la Mata de, M., Iñarrairaegui, M., Garralda, E., Barrera, P., et al. A clinical trial of CTLA-4 blockade with tremelimumab in patients with hepatocellular carcinoma and chronic hepatitis C. J Hepatol 59 (2013), 81–88.
17. Duffy, A.G., Ulahannan, S.V., Makorova-Rusher, O., Rahma, O., Wedemeyer, H., Pratt, D., et al. Tremelimumab in combination with ablation in patients with advanced hepatocellular carcinoma. J Hepatol 66 (2017), 545–551.
18. Sprinzl, M.F., Galle, P.R., Current progress in immunotherapy of hepatocellular carcinoma. J Hepatol 66 (2017), 482–484.
19. Shi, F., Shi, M., Zeng, Z., Qi, R.-Z., Liu, Z.-W., Zhang, J.-Y., et al. PD-1 and PD-L1 upregulation promotes CD8(+) T-cell apoptosis and postoperative recurrence in hepatocellular carcinoma patients. Int J Cancer 128 (2011), 887–896.
20. Gao, Q., Wang, X.-Y., Qiu, S.-J., Yamato, I., Sho, M., Nakajima, Y., et al. Overexpression of PD-L1 significantly associates with tumour aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res 15 (2009), 971–979.
21. Wang, B.-J., Bao, J.-J., Wang, J.-Z., Wang, Y., Jiang, M., Xing, M.-Y., et al. Immunostaining of PD-1/PD-Ls in liver tissues of patients with hepatitis and hepatocellular carcinoma. World J Gastroenterol 17 (2011), 3322–3329.
22. El-Khoueiry, A.B., Sangro, B., Yau, T., Crocenzi, T.S., Kudo, M., Hsu, C., Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial. Lancet 389:10088 (2017), 2492–2502.
23. Crocenzi, T.S., el-khoueiry, A.B., yau, T., Melero, I., Sangro, B., Kudo, M., et al. Nivolumab in sorafenib-naive and -experienced patients with advanced hepatocellular carcinoma: CheckMate 040 study. J Clin Oncol, 35(15 suppl.), 2017, 4013.
24. Kavanagh, B., O'Brien, S., Lee, D., Hou, Y., Weinberg, V., Rini, B., et al. CTLA4 blockade expands FoxP3+ regulatory and activated effector CD4+ T cells in a dose-dependent fashion. Blood 112 (2008), 1175–1183.
25. O'Donnell, J.S., Long, G.V., Scolyer, R.A., Teng, M.W.L., Smyth, M.J., Resistance to PD1/PDL1 checkpoint inhibition. Cancer Treat Rev 52 (2017), 71–81.
26. Sharma, P., Hu-Lieskovan, S., Wargo, J.A., Ribas, A., Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell 168 (2017), 707–723.
27. Schumacher, T.N., Schreiber, R.D., Neoantigens in cancer immunotherapy. Science 348 (2015), 69–74.
28. Twyman-Saint Victor, C., Rech, A.J., Maity, A., Rengan, R., Pauken, K.E., Stelekati, E., et al. Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer. Nature 520 (2015), 373–377.
29. Emens, L.A., Cancer vaccines: on the threshold of success. Expert Opin Emerg Drugs 13 (2008), 295–308.
30. Buonaguro L, HEPAVAC Consortium. Developments in cancer vaccines for hepatocellular carcinoma. Cancer Immunol Immunother 65 (2016), 93–99.
31. Bald, T., Landsberg, J., Lopez-Ramos, D., Renn, M., Glodde, N., Jansen, P., et al. Immune cell-poor melanomas benefit from PD-1 blockade after targeted type I IFN activation. Cancer Discov 4 (2014), 674–687.
32. Gabrilovich, D.I., Ishida, T., Nadaf, S., Ohm, J.E., Carbone, D.P., Antibodies to vascular endothelial growth factor enhance the efficacy of cancer immunotherapy by improving endogenous dendritic cell function. Clin Cancer Res 5 (1999), 2963–2970.
33. Zippelius, A., Schreiner, J., Herzig, P., Müller, P., Induced PD-L1 expression mediates acquired resistance to agonistic anti-CD40 treatment. Cancer Immunol Res 3 (2015), 236–244.
34. Sánchez-Paulete, A.R., Cueto, F.J., Martínez-López, M., Labiano, S., Morales-Kastresana, A., Rodríguez-Ruiz, M.E., et al. Cancer immunotherapy with immunomodulatory anti-CD137 and anti-PD-1 monoclonal antibodies requires BATF3-dependent dendritic cells. Cancer Discov 6 (2016), 71–79.
35. Ngiow, S.F., Young, A., Jacquelot, N., Yamazaki, T., Enot, D., Zitvogel, L., et al. A threshold level of intratumour CD8+ T-cell PD1 expression dictates therapeutic response to anti-PD1. Cancer Res 75 (2015), 3800–3811.
36. Wolchok, J.D., Saenger, Y., The mechanism of anti-CTLA-4 activity and the negative regulation of T-cell activation. Oncologist 13 (2008), 2–9.
37. Postow, M.A., Chesney, J., Pavlick, A.C., Robert, C., Grossmann, K., McDermott, D., et al. Nivolumab and ipilimumab vs. ipilimumab in untreated melanoma. N Engl J Med 372 (2015), 2006–2017.
38. Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J.-J., Cowey, C.L., Lao, C.D., et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N Engl J Med 373 (2015), 23–34.
39. Bulliard, Y., Jolicoeur, R., Zhang, J., Dranoff, G., Wilson, N.S., Brogdon, J.L., OX40 engagement depletes intratumoural Tregs via activating FcγRs, leading to antitumour efficacy. Immunol Cell Biol 92 (2014), 475–480.
40. Guo, Z., Wang, X., Cheng, D., Xia, Z., Luan, M., Zhang, S., PD-1 blockade and OX40 triggering synergistically protects against tumour growth in a murine model of ovarian cancer. PLoS One, 9, 2014, e89350.
41. Sakuishi, K., Apetoh, L., Sullivan, J.M., Blazar, B.R., Kuchroo, V.K., Anderson, A.C., Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumour immunity. J Exp Med 207 (2010), 2187–2194.
42. Ribas, A., Shin, D.S., Zaretsky, J., Frederiksen, J., Cornish, A., Avramis, E., et al. PD-1 blockade expands intratumoural memory T Cells. Cancer Immunol Res 4 (2016), 194–203.
43. Lee, J.H., Lee, J.-H., Lim, Y.-S., Yeon, J.E., Song, T.-J., Yu, S.J., et al. Adjuvant immunotherapy with autologous cytokine-induced killer cells for hepatocellular carcinoma. Gastroenterology 148 (2015), 1383–1386.
44. Butterfield, L.H., Ribas, A., Dissette, V.B., Lee, Y., Yang, J.Q., la Rocha de, P., et al. A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides. Clin Cancer Res 12 (2006), 2817–2825.
45. Palmer, D.H., Midgley, R.S., Mirza, N., Torr, E.E., Ahmed, F., Steele, J.C., et al. A phase II study of adoptive immunotherapy using dendritic cells pulsed with tumour lysate in patients with hepatocellular carcinoma. Hepatology 49 (2008), 124–132.
46. Fesnak, A.D., June, C.H., Levine, B.L., Engineered T cells: the promise and challenges of cancer immunotherapy. Nat Rev Cancer 16 (2016), 566–581.
47. Ho, M., Kim, H., Glypican-3: a new target for cancer immunotherapy. Eur J Cancer 47 (2011), 333–338.
48. Gao, H., Li, K., Tu, H., Pan, X., Jiang, H., Shi, B., et al. Development of T cells redirected to glypican-3 for the treatment of hepatocellular carcinoma. Clin Cancer Res 20 (2014), 6418–6428.
49. Sun, L., Guo, H., Jiang, R., Lu, L., Liu, T., He, X., Engineered cytotoxic T lymphocytes with AFP-specific TCR gene for adoptive immunotherapy in hepatocellular carcinoma. Tumour Biol 37 (2016), 799–806.
50. Llovet, J.M., Decaens, T., Raoul, J.-L., Boucher, E., Kudo, M., Chang, C., et al. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J Clin Oncol 31 (2013), 3509–3516.
51. Zhu, A.X., Kudo, M., Assenat, E., Cattan, S., Kang, Y.-K., Lim, H.Y., et al. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial. JAMA 312 (2014), 57–67.
52. Zhu, A.X., Park, J.O., Ryoo, B.-Y., Yen, C.-J., Poon, R., Pastorelli, D., et al. Ramucirumab vs. placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol 16 (2015), 859–870.